Angioimmunoblastic T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Angioimmunoblastic T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [Phase 3]
Phase 3 trial evaluating efficacy and safety of oral azacitidine (CC-486) versus investigator's choice therapy in relapsed or refractory ang…
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [Phase 3]
Phase 3 trial evaluating oral azacitidine (CC-486) versus investigator's choice in relapsed or refractory angioimmunoblastic T-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of romidepsin and lenalidomide in previously untreated peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-01-25Clinical Trial Update: Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL [Phase 1, Phase 2]
A clinical trial investigating mitoxantrone liposome combined with azacitidine for angioimmunoblastic T-cell lymphoma is in Phase 1/2, with …
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating brentuximab vedotin in combination chemotherapy for CD30-positive peripheral T-cell lymphomas reports results poste…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2023-02-21Clinical Trial Update: CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) [Phase 2, Phase 3]
Clinical trial CELTIC-1 evaluating cerdulatinib in relapsed/refractory peripheral T-cell lymphoma has been withdrawn from the study.
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms [Phase 2]
Phase 2 study of BGB-A317 (tislelizumab) in adults with relapsed or refractory mature T- and NK-cell neoplasms has completed, with results p…
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma [Phase 2]
Phase 2 trial evaluating safety and efficacy of C-CHOP in untreated angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating azacytidine plus chidamide for relapsed and refractory angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) [Phase 2]
Phase 2 trial update evaluating CHOP plus lenalidomide as first-line therapy in angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating combination chemotherapy with lenalidomide in newly diagnosed peripheral T-cell lymphoma (multiple subtypes) ha…
-
CLINICAL_TRIALS trial_result · 2021-04-05Clinical Trial Update: Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL [Phase 2]
Phase 2 trial exploring sintilimab in combination with chidamide for refractory and relapsed angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation [Phase 1, Phase 2]
Clinical trial update for enasidenib (AG-221) in adults with advanced solid tumors, glioma, or angioimmunoblastic T-cell lymphoma harboring …
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma [Phase 2]
Phase 2 clinical trial of plitidepsin in relapsed or refractory angioimmunoblastic T-cell lymphoma was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL [Phase 1, Phase 2]
Clinical trial update for lenalidomide plus CHOP in untreated peripheral T-cell lymphoma (PTCL) across early phases; status not specified.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL [Phase 2]
Phase 2 trial comparing CEOP/IVE/GDP to CEOP as first-line therapy for adults with peripheral T-cell lymphoma subtypes; status currently unk…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]
Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-06-25Clinical Trial Update: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy with pralatrexate as first-line therapy for non-Hodgkin lymphomas, including various T-cel…
-
CLINICAL_TRIALS research · 2018-03-15Clinical Trial Update: CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study [Phase 2]
Multicentre Phase II trial comparing CHOP versus GEM-P as first-line therapy for various peripheral T-cell lymphomas; current study status i…
-
CLINICAL_TRIALS research · 2017-11-14Clinical Trial Update: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma [Phase 4]
A Phase 4 clinical trial compares the CTOP/ITE/MTX regimen against CHOP as first-line therapy for newly diagnosed young patients with variou…
-
CLINICAL_TRIALS trial_result · 2017-09-25Clinical Trial Update: Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) [Phase 2]
Phase 2 trial evaluating chidamide in combination with a PET regimen (Prednisone, Etoposide, Thalidomide) for angioimmunoblastic T-cell lymp…
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies [Phase 2]
A Phase 2 trial evaluating a combination of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with previously treated lymph…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.